Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/23012
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBensadoun, R.-
dc.contributor.authorSchubert, M.-
dc.contributor.authorLalla, R.-
dc.contributor.authorKeefe, D.-
dc.date.issued2006-
dc.identifier.citationSupportive Care in Cancer, 2006; 14(6):566-572-
dc.identifier.issn0941-4355-
dc.identifier.issn1433-7339-
dc.identifier.urihttp://hdl.handle.net/2440/23012-
dc.descriptionThe original publication can be found at www.springerlink.com-
dc.description.abstractIntroduction Mucositis is a significant complication of cancer therapy, with important clinical and economic implications. In June 2005, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) conducted an evidence-based update review of the literature on mucositis. The goal of this literature review is to update previously published guidelines for the management of mucositis. Results This article reports the findings of the subgroup charged with reviewing the literature related to amifostine.-
dc.description.statementofresponsibilityRene-Jean Bensadoun, Mark M. Schubert, Rajesh V. Lalla and Dorothy Keefe-
dc.language.isoen-
dc.publisherSpringer-Verlag-
dc.source.urihttp://www.springerlink.com/content/5857l17202n61457/-
dc.subjectamifostine-
dc.subjectmucositis-
dc.subjectradiotheraphy-
dc.subjectchemotheraphy-
dc.titleAmifostine in the management of radiation-induced and chemo-induced mucositis-
dc.typeJournal article-
dc.identifier.doi10.1007/s00520-006-0047-4-
pubs.publication-statusPublished-
dc.identifier.orcidKeefe, D. [0000-0001-9377-431X]-
Appears in Collections:Aurora harvest 2
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.